Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who give their consent to take part in the study
- People who have been diagnosed with cancer of the oesophagus (food pipe), stomach, or pancreas at an early stage (stage 0 to 2)
- People with cancer that has not spread far but may be able to be removed with surgery, who are being treated with chemotherapy or a combination of chemotherapy and radiation therapy around the time of surgery
- People with cancer that has spread to other parts of the body, who are receiving chemotherapy or other systemic treatments aimed at managing the disease (first, second, or third course of such treatment)
Who may not be able to join:
- No exclusion criteria have been specified for this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Petr Müller, MD, PhD, Masaryk Memorial Cancer Institute
Phone: +420543136232
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of targeted NGS assay for ctDNA mutation detection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.